There is no easily quantifiable amount per prescription, but targets around statins and diabetes are included within the indicators of the Quality and Outcomes Framework (QOF) which according to the
King’s Fund accounts for approximately 10% of GP surgery income. The exact payments are based upon a points based system measured against a series of indicators.
Quality and Outcomes Framework payments
The Quality and Outcomes Framework accounts for around 10 per cent of a practice’s income. The Quality and Outcomes Framework is a voluntary programme that practices can opt in to in order to receive payments based on good performance against a number of indicators. In 2018/19 more than
95 per cent of practices took part. The framework covers a range of clinical areas, for example, management of hypertension or asthma; prescribing safety; or ill health prevention activity. Each area has a range of indicators that equate to a number of Quality and Outcomes Framework points.
One such indicator in the
Diabetes Mellitus section is as follows:
‘DM022. The percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a CVD risk score of <10% recorded in the preceding 3 years)’
So yes, there is a financial incentive to prescribe statins.
You might find a read of the full King’s Fund report (linked) eye opening.
To directly answer
@michelle88 I’d want to see evidence from my doctor in relation to their claim, which I have not seen mentioned elsewhere.